Go back

Public-private dementia consortium to open £3m drug-discovery call

A consortium bringing together government and industry funding for dementia research has announced it will soon open an international funding call for academic teams to develop drug targets for treating dementia.

The group is made up of the charity Alzheimer’s Research UK, the Medical Research Council’s tech transfer branch, MRC Technology, and two pharmaceutical companies, Eisai and Lilly. They have come together with the aim of reducing the gap between basic academic research and commercial drug discovery programmes.

ARUK is contributing £2m to the programme and the two companies are each contributing £500,000. MRC Technology plans to provide support for researchers to confirm drug targets through its Centre for Therapeutics Discovery.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.